Windtree Therapeutics, Inc. (WINT)
After hours:
| Previous Close | 0.5093 |
| Open | 0.5000 |
| Bid | 0.4708 x 100 |
| Ask | 0.5254 x 100 |
| Day's Range | 0.4900 - 0.5106 |
| 52 Week Range | 0.4500 - 22.3200 |
| Volume | |
| Avg. Volume | 1,734,434 |
| Market Cap | 4.399M |
| Beta (5Y Monthly) | 0.64 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -19.0300 |
| Earnings Date | Nov 25, 2024 - Nov 29, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 7.00 |
GlobeNewswireWindtree Announces Leadership Transition Plan With Industry Veterans
Jed Latkin to transition to CEOWARRINGTON, Pa., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases, today announced that Craig Fraser plans to retire from his role as Chief Executive Officer, effective December 1, 2024, after nearly nine years of distinguished service to the Company. Mr. Fraser will remain on the Bo
Zacks Small Cap ResearchWINT: Patient Enrollment in SEISMiC C Trial Starts, Patent Position Expands
By M. Marin NASDAQ:WINT Enrolling SCAI Stage C participants in SEISMiC C trial, preparing for Phase 3 readiness Pennsylvania-based Windtree Therapeutics, Inc. (NASDAQ:WINT), a biopharmaceutical company developing therapies for a range of cardiovascular and oncology treatments characterized by significant unmet need, implemented a number of measures recently to move lead asset istaroxime forward.
